| 영문 | prothrombin time | 한글 | 프로트롬빈시간 |
|---|---|---|---|
| 설명 | 프로트롬빈은 간에서 합성되는 비타민 K 의존성 응고단백질의 하나이며, 프로트롬빈시간은 외인계 응고활성을 종합적으로 특정하는 검사의 하나이다. 피검혈장에 칼슘이온과 조직트롬보플라스틴(제III 응고인자)을 가해, 섬유소가 나타날 때까지의 시간으 측정한다. |
||
| 영문 | rheumatoid factor | 한글 | 류마티스 인자 |
|---|---|---|---|
| 설명 | IgG의 Fc부위에 있는 항원결정인자에 대한 항체로서 전형적인 또는 확실한 류마티스관절염(rheumatoid arthritis) 환자의 80%에서 발견된다. 류마티스 인자는 IgM, IgG, IgA중 하나가 될 수 있으나 주로 IgM이다. 소아류마티스관절염(juvenile rheumatoid arthritis: 소아기에 발생하는 류마티스관절염)을 비롯한, 다른 결합조직병이나 감염병에도 나타날 수 있다 |
||
| 영문 | growth factor | 한글 | 성장인자 |
|---|---|---|---|
| 설명 | 세포의 분화 및 성장에 관여하는 단백질. 성장인자는 정상 세포주기에 필수적이기 때문에 동물의 생명에 중대한 요소가 된다. 무엇보다도 성장인자는 태아의 발육을 조정하고 조직의 유지 및 보수에 중대한 역할을 하며, 혈구의 생성을 자극한다. 또한 암의 진행과정에도 관여한다. |
||
| 영문 | risk factor | 한글 | 위험인자 |
|---|---|---|---|
| 설명 | 국제방사선방호위원회(ICRP)가 1977년 권고에서 방사선방호의 목적으로 채택한 지수로, 단위선량(1 Sv)당 확률적 영향의 발생확률을 추정하여 나타낸 것이다. 생식선 선량에 대한 유전적영향의 발생률(4×10－3/Sv)이나 적색골수선량에 대한 백혈병 발생률(2×10－3/Sv)등 외에 뼈, 허파, 갑상샘, 젖샘, 기타 조직의 위험지수를 측정하여, 확률적 영향의 전신에 있어서 치사위험지수의 합계를 16.5×10－3/Sv로 하였다. 그후 ICRP는 1990년 권고에서 대상이 되는 조직과 장기를 추가하고, 수치 개정을 하면서 명칭도 각목적확률지수라고하였다. 이 권고에 의하면, 치사적 확률적 영향의 확률지수의 합계는, 일반인에 있어 60.0×10－3/Sv이다. |
||
| 영문 | serum | 한글 | 혈청 |
|---|---|---|---|
| 설명 | 혈액의 성분 중 고형성분인 혈구세포(적혈구, 백혈구 등), 혈소판을 제외한 부분을 혈장이라고 하고, 혈장에서 섬유소를 제외한 부분을 혈청이라고 한다. |
||
| SF | Sabin-Feldman [test]; safety factor; salt-free; scarlet fever; screen film; seminal fluid; serosal f... |
|---|---|
| CF | calcaneal fibular [ligament]; calcium leucovorin; calf blood flow; calibration factor; cancer-free; ... |
| PPCA | plasma prothrombin conversion accelerator; proserum prothrombin conversion accelerator |
| EF | ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e... |
| PF | pair feeding; peak flow; perfusion fluid; pericardial fluid; periosteal fibroblast; peritoneal fluid... |
| SACE | Serum Angiotensin Converting Enzyme |
|---|---|
| SACE | Serum angiotensin-converting enzyme activity |
| TACE | factor alpha converting enzyme |
| DCP | Des-gamma-carboxy prothrombin |
| PCC | Prothrombin Complex Concentrates |
IGF-II : insulin like growth factor-II의 약자. 많은 장기와 조직에 작용하여 단백 합성과 DNA, RNA의 합성을 증가시켜 세포의 수와 양을 증가
| serum prothrombin conversion accelerator | <chemical> Heat- and storage-stable plasma protein that is activated by tissue thromboplastin to form factor viia in the extrinsic pathway of blood coagulation. The activated form then catalyses the activation of factor x to factor xa. Chemical name: Blood-coagulation factor VII (12 Dec 1998) |
|---|---|
| angiotensin-converting enzyme | <enzyme> This hydrolase enzyme cleaves the decapeptide angiotensin I (biologically inactive) to form active angiotensin II by angiotensin-converting enzyme which removes a dipeptide (histidylleucine) from angiotensin I. Angiotensin II causes contraction of vascular smooth muscle and thus raises blood pressure and stimulates aldosterone release from the adrenal glands. Angiotensin is finally broken down by angiotensinases. Elevations in angiotensin converting enzyme are seen sarcoidosis, histoplasmosis, alcoholic cirrhosis, asbestosis, berylliosis, diabetes, Hodgkin's disease, hyperthyroidism, amyloidosis, primary biliary cirrhosis, idiopathic pulmonary fibrosis, pulmonary embolism, scleroderma, silicosis, tuberculosis, Gaucher's disease and leprosy. The normal values are 18 to 67 U/ml over 20 years of age (people under 20 have higher levels). Drugs that inhibit ACE are used to treat hypertension and congestive heart failure. See: angiotensin-converting enzyme inhibitor Acronym: ACE (12 Aug 2000) |
| angiotensin-converting enzyme inhibitor | <pharmacology> A class of drugs used in the treatment of hypertension and heart failure. They exert their haemodynamic effect mainly by inhibiting the renin-angiotensin system and produce a reduction of peripheral arterial resistance. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (14 Aug 2000) |
| angiotensin-converting enzyme secretase | <enzyme> Converts ace from a membrane-bound to a soluble form; not inhibited by thiol, serine or acid enzyme inhibitor but is inhibited by edta and 1,10-phenanthroline Registry number: EC 3.4.99.- Synonym: ace secretase (26 Jun 1999) |
| vasopressin-converting aminopeptidase | <enzyme> Activity found in brain which converts vasopressin into centrally active metabolites Registry number: EC 3.4.11.- Synonym: vp-c aminopeptidase (26 Jun 1999) |
| dynorphin-converting endopeptidase | <enzyme> Enzyme from human cerebrospinal fluid; cleaves dynorphin a and b and neoendorphin at the arg(6)-arg(7) or arg(6)-lys(7) bonds Registry number: EC 3.4.21.- Synonym: dynorphin-neo-endorphin endopeptidase, dc-endopeptidase (26 Jun 1999) |
| interleukin-1 converting enzyme | <biochemistry> Cytoplasmic cysteine protease that is uniquely responsible for cleaving proIL-1_ (31 or 33 kD) into mature IL-1_ (17.5 kD), the active cytokine is then released by a nonstandard mechanism (there is no signal sequence and it does not pass through the Golgi). The enzyme seems to be composed of two nonidentical subunits derived from a single proenzyme. The ICE gene has some homology with the ced 9 gene of C. Elegans, the product of which is involved in mediating cell death by apoptosis. (11 Mar 1998) |
| urokinase-converting protease | <enzyme> Degrades synthetic urokinase substrates and stimulates urokinase Registry number: EC 3.4.21.- Synonym: urokinase cofactor (26 Jun 1999) |
| proserum prothrombin conversion accelerator | A coagulation (clotting) factor. Classic haemophilia (haemophilia A) is due to a congenital deficiency in the amount (or activity) of factor VIII. Factor VIII is also known as antihemophiliac factor (AHF) or antihemophiliac globulin (AHG). The gene for factor VIII (that for classic haemophilia) is on the X chromosome so females can be silent carriers without symptoms and males can be haemophiliacs. (12 Dec 1998) |
| prothrombin | Clotting Factor II. Origin: Gr. Thrombos = cloth in (18 Nov 1997) |
| prothrombin accelerator | <chemical> Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor v accomplishes this by forming a complex with factor xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor v leads to owren's disease. Chemical name: Blood-coagulation factor V (12 Dec 1998) |
| prothrombin and proconvertin test | A test formerly used by some to control anticoagulant therapy with bishydroxycoumarin and indandione drugs. Synonym: P and P test. (05 Mar 2000) |
| prothrombin deficiency | A congenital or acquired disorder of blood clotting where there is a deficiency of factor II (prothrombin), one of 20 necessary plasma proteins for normal blood coagulation. Acquired factor II deficiency may result from vitamin K deficiency, severe liver disease and anticoagulant drugs. Symptoms include abnormal bleeding, nosebleeds, abnormal menstrual bleeding, easy bruising and umbilical cord bleeding at birth. Treatment involves the infusion of fresh frozen plasma. Vitamin K may be administered in select cases. (27 Sep 1997) |
| prothrombin test | A quantitative test for prothrombin in the blood based on the clotting time of oxalated blood plasma in the presence of thromboplastin and calcium chloride; measures the integrity of the extrinsic and common pathways of coagulation. See: prothrombin time. Synonym: Quick's method, Quick's test. (05 Mar 2000) |
| prothrombin time | Measurement of clotting time of plasma recalcified in the presence of excess tissue thromboplastin. Factors measured are fibrinogen, prothrombin, and factors v, vii, and x. It is used for monitoring anticoagulant therapy with coumarins. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|